---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-000943"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:40:26.923415+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BridgeBio reports early Attruby demand: 430 scripts from 248 physicians; three Phase 3 trials fully enrolled

## Summary
- Attruby (acoramidis) approved Nov 22, 2024; 430 prescriptions by 248 unique HCPs since launch.
- Three Phase 3 trials fully enrolled: FORTIFY (LGMD2I/R9, n=112), CALIBRATE (ADH1, n=70), PROPEL 3 (achondroplasia, n=114).
- Cash $406M last quarter; received $500M upon acoramidis FDA approval from royalty facility; expects $105M milestones in 1H 2025.
- Milestones: EU/Japan acoramidis approvals in 1H 2025; topline readouts FORTIFY & CALIBRATE in 2H 2025; PROPEL 3 LPLV in 2H 2025.

## SEC filing metadata
- accession: 0001140361-25-000943
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036125000943/0001140361-25-000943-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036125000943/ef20041481_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-000943
- JSON: https://secwatch.observer/filing/0001140361-25-000943.json
- Plain text: https://secwatch.observer/filing/0001140361-25-000943.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.